NASDAQ:GILD - Gilead Sciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $66.89 -0.28 (-0.42 %) (As of 05/24/2019 04:00 PM ET)Previous Close$67.17Today's Range$66.4529 - $67.475052-Week Range$60.32 - $79.61Volume3.51 million shsAverage Volume7.23 million shsMarket Capitalization$85.28 billionP/E Ratio10.88Dividend Yield3.75%Beta1.14 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; and insitro Inc. The company was founded in 1987 and is headquartered in Foster City, California. Receive GILD News and Ratings via Email Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GILD Previous Symbol CUSIP37555810 CIK882095 Webhttp://www.gilead.com/ Phone650-574-3000Debt Debt-to-Equity Ratio1.09 Current Ratio3.62 Quick Ratio3.53Price-To-Earnings Trailing P/E Ratio10.88 Forward P/E Ratio10.13 P/E Growth0.81 Sales & Book Value Annual Sales$22.13 billion Price / Sales3.85 Cash Flow$7.3667 per share Price / Cash Flow9.08 Book Value$17.33 per share Price / Book3.86Profitability EPS (Most Recent Fiscal Year)$6.15 Net Income$5.46 billion Net Margins26.40% Return on Equity37.98% Return on Assets13.10%Miscellaneous Employees11,000 Outstanding Shares1,274,896,000Market Cap$85.28 billion Next Earnings Date7/24/2019 (Estimated) OptionableOptionable Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions What is Gilead Sciences' stock symbol? Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD." How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences? Gilead Sciences announced a quarterly dividend on Thursday, May 2nd. Investors of record on Friday, June 14th will be paid a dividend of $0.63 per share on Thursday, June 27th. This represents a $2.52 annualized dividend and a yield of 3.77%. The ex-dividend date is Thursday, June 13th. View Gilead Sciences' Dividend History. How were Gilead Sciences' earnings last quarter? Gilead Sciences, Inc. (NASDAQ:GILD) announced its earnings results on Thursday, May, 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating the Zacks' consensus estimate of $1.53 by $0.23. The biopharmaceutical company had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. Gilead Sciences's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.48 EPS. View Gilead Sciences' Earnings History. When is Gilead Sciences' next earnings date? Gilead Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for Gilead Sciences. What guidance has Gilead Sciences issued on next quarter's earnings? Gilead Sciences issued an update on its FY 2019 earnings guidance on Thursday, May, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $21.3-21.8 billion, compared to the consensus revenue estimate of $21.96 billion. What price target have analysts set for GILD? 21 equities research analysts have issued 1-year target prices for Gilead Sciences' stock. Their forecasts range from $66.80 to $95.00. On average, they anticipate Gilead Sciences' share price to reach $81.2111 in the next year. This suggests a possible upside of 21.4% from the stock's current price. View Analyst Price Targets for Gilead Sciences. What is the consensus analysts' recommendation for Gilead Sciences? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences. What are Wall Street analysts saying about Gilead Sciences stock? Here are some recent quotes from research analysts about Gilead Sciences stock: 1. Needham & Company LLC analysts commented, "Gilead reported $5.28B in 1Q19 total revenue, in line w/ our $5.27B and consensus $5.3B ests. Product sales were $5.20B (-8% q/q), matching our $5.16B and consensus $5.2B ests. Mgmt had guided for 12-14% sequential decline. All annual guidance unch. Non-GAAP EPS $1.76 was above our $1.64 and consensus $1.61 ests. New CEO O’Day outlined priorities (Strengthen pipeline [internal and external business development]; Ensure optimal commercial delivery; and Reassess organizational structure [‘evolution not revolution’]) and announced that Kite will operate as a separate business unit w/ a new CEO reporting directly to O’Day. Filgotinib MAA to be submitted 3Q19, but no update yet on strategy/ timing for NDA submission. NASH ATLAS drug combination trial results expected 4Q19 (unch). HOLD." (5/6/2019) 2. Cowen Inc analysts commented, "NTLA reported 1Q results of $10.4M in collaboration revenue, $34M in -$0.49 vs consensus EPS of -$0.57. 1Q cash balance was $296.6M, which management estimates will fund operations into 1H 2021. The call included several updates on the pipeline in in-vivo editing and ex-vivo engineered T-Cells: 1) NTLA remains on track for NDA submission of NTLA-2001 for ATTR in 2020 and preparations (manufacturing & toxicology) are ongoing. 2) Data presented at ASGCT was the first demonstration of CRISPR/Cas9-based targeted insertion in the liver of non-human primates. We view this as a validation of NTLA’s modular LNP+AAV approach to in-vivo editing. 3) ASGCT presentation on engineered cell therapy (WT1 insertion into >95% of isolated T-cells) shows progress in cell therapy." (5/3/2019) 3. According to Zacks Investment Research, "Gilead’s HIV franchise maintains momentum, driven by continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. However, the company’s HCV franchise continues to witness a slowdown across key markets, including the United States and Europe, as a result of competition and pricing pressure. Consequently, Gilead shifted focus to its HIV franchise, and newer avenues like CAR-T therapy and NASH. However, the company suffered a setback with the failure of a late-stage study on selonsertib in patients with compensated cirrhosis (F4) due to NASH. Shares have underperformed the industry in the past three months." (5/2/2019) 4. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $87 Price Target. We do not think today’s announcement that GILD’s STELLAR3 study was unsuccessful will be met with much surprise after the previous STELLAR4 failure: no changes to our estimates. The fibrosis improvement was least for the high dose and greatest for the placebo with a p-value at the higher dose of 0.42 and at lower dose it was 0.93. After both STELLAR Ph3 readouts we are focused on how Gilead will advance its strategy in NASH; we think M&A could be a strategy." (4/25/2019) 5. Mizuho analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (4/22/2019) Has Gilead Sciences been receiving favorable news coverage? Press coverage about GILD stock has trended positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Gilead Sciences earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of Gilead Sciences' key competitors? Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN) and Acceleron Pharma (XLRN). What other stocks do shareholders of Gilead Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Celgene (CELG), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Walt Disney (DIS), Intel (INTC), NVIDIA (NVDA), Bank of America (BAC), AT&T (T) and Starbucks (SBUX). Who are Gilead Sciences' key executives? Gilead Sciences' management team includes the folowing people: Ms. Robin L. Washington, CFO & Exec. VP (Age 56)Dr. John G. McHutchison M.D., FRACP, Chief Scientific Officer and Head of R&D (Age 61)Mr. Gregg H. Alton, Chief Patient Officer (Age 53)Ms. Laura Hamill, Exec. VP of Worldwide Commercial Operations (Age 54)Mr. Daniel O'Day, Chairman & CEO (Age 55) Who are Gilead Sciences' major shareholders? Gilead Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.04%), Geode Capital Management LLC (1.38%), Northern Trust Corp (1.32%), Parnassus Investments CA (1.03%), FMR LLC (1.01%) and Sanders Capital LLC (0.89%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, Richard James Whitley and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences. Which institutional investors are selling Gilead Sciences stock? GILD stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Boston Partners, BlackRock Inc., FMR LLC, FIL Ltd, Janus Henderson Group PLC, Wellington Management Group LLP and State Treasurer State of Michigan. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, John C Martin, John Francis Cogan and Richard James Whitley. View Insider Buying and Selling for Gilead Sciences. Which institutional investors are buying Gilead Sciences stock? GILD stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Parnassus Investments CA, Geode Capital Management LLC, Charles Schwab Investment Management Inc., State of Tennessee Treasury Department, Sanders Capital LLC, Candriam Luxembourg S.C.A. and Toronto Dominion Bank. View Insider Buying and Selling for Gilead Sciences. How do I buy shares of Gilead Sciences? Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Gilead Sciences' stock price today? One share of GILD stock can currently be purchased for approximately $66.89. How big of a company is Gilead Sciences? Gilead Sciences has a market capitalization of $85.28 billion and generates $22.13 billion in revenue each year. The biopharmaceutical company earns $5.46 billion in net income (profit) each year or $6.15 on an earnings per share basis. Gilead Sciences employs 11,000 workers across the globe. What is Gilead Sciences' official website? The official website for Gilead Sciences is http://www.gilead.com/. How can I contact Gilead Sciences? Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected] MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 2,048 (Vote Outperform)Underperform Votes: 930 (Vote Underperform)Total Votes: 2,978MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: What are momentum indicators and what do they show? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.